A three-dose course of AstraZeneca’s COVID-19 vaccine is effective against the omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against imicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19.
After a three-dose course of the vaccine, neutralizing levels against omicron were similar to those against the virus’s delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.
Omicron hospitalization risk is far below delta’s in two studiesThe omicron variant of Covid-19 may be less likely to land patients in the hospital than the delta strain, according to a trio of studies of ... Coronavirus
Australian states reinstate COVID-19 curbs as omicron cases jumpAustralia’s two most populous states re-introduced COVID-19 curbs on Thursday as daily infections hit their highest amid an outbreak of the highly ... Coronavirus
Olympics: China expects COVID cases due to Games arrivals, flags omicron riskOrganizers of the Beijing Winter Olympics said on Thursday they expect a “certain number” of COVID-19 cases in China due to foreigners arriving for ... World News